Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
50°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
161.99
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
256
Open
161.99
Bid (Size)
161.73 (1)
Ask (Size)
162.54 (1)
Prev. Close
161.99
Today's Range
161.99 - 161.99
52wk Range
143.13 - 168.85
Shares Outstanding
2,628,679,824
Dividend Yield
2.94%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
September 30, 2024
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by...
Via
Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
September 30, 2024
These 15 dividend stocks can deliver stable passive income for life.
Via
The Motley Fool
Performance
YTD
+1.26%
+1.26%
1 Month
-3.09%
-3.09%
3 Month
+10.93%
+10.93%
6 Month
+2.70%
+2.70%
1 Year
+4.41%
+4.41%
More News
Read More
2 Excellent Dividend Stocks to Buy With Less Than $200
September 28, 2024
Via
The Motley Fool
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
September 27, 2024
Via
Investor's Business Daily
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
September 27, 2024
Via
Benzinga
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
September 26, 2024
Via
Benzinga
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
September 23, 2024
Via
Chartmill
The Latest Analyst Ratings For Johnson & Johnson
September 19, 2024
Via
Benzinga
For those who appreciate value investing, NYSE:JNJ is a compelling option with its solid fundamentals.
September 27, 2024
Via
Chartmill
Why Masimo Stock Crushed the Market Today
September 25, 2024
Via
The Motley Fool
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
Via
Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
September 25, 2024
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Johnson & Johnson
September 12, 2024
Via
Benzinga
Is Johnson & Johnson Stock a Buy?
September 21, 2024
Via
The Motley Fool
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
September 20, 2024
From
Beasley Allen Law Firm
Via
Business Wire
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
September 20, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
September 20, 2024
Via
Benzinga
Exposures
Product Safety
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
September 20, 2024
Via
Benzinga
Exposures
Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
September 19, 2024
Via
The Motley Fool
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
Via
Benzinga
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
September 17, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.